John F Seymour

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8228933/publications.pdf

Version: 2024-02-01

626	45,629	2213	2381
papers	citations	99 h-index	198 g-index

631	631	631	29254
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine, 2013, 19, 202-208.	15.2	2,426
2	Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncology, The, 2009, 10, 223-232.	5.1	2,404
3	Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, The, 2010, 376, 1164-1174.	6.3	1,713
4	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2016, 374, 311-322.	13.9	1,532
5	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 2018, 131, 2745-2760.	0.6	1,069
6	International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood, 2015, 126, 291-299.	0.6	982
7	Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet, The, 2011, 377, 42-51.	6.3	957
8	Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 562-569.	0.8	886
9	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood, 2009, 113, 4834-4840.	0.6	829
10	Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma. Journal of Clinical Oncology, 2005, 23, 5034-5043.	0.8	729
11	Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. Journal of Clinical Oncology, 2012, 30, 488-496.	0.8	719
12	Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood, 2003, 102, 276-283.	0.6	707
13	Venetoclaxâ€“Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2018, 378, 1107-1120.	13.9	684
14	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncology, The, 2016, 17, 768-778.	5.1	676
15	Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood, 2013, 122, 515-522.	0.6	641
16	Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 215-235.	2.5	607
17	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. Journal of Clinical Oncology, 2017, 35, 826-833.	0.8	596
18	Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. New England Journal of Medicine, 2017, 377, 1331-1344.	13.9	575

#	Article	IF	Citations
19	Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood, 2016, 127, 208-215.	0.6	571
20	Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the â€˜cutaneous variantâ€™1. British Journal of Haematology, 2004, 127, 173-183.	1.2	535
21	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022, 140, 1229-1253.	0.6	512
22	Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood, 2006, 108, 4003-4008.	0.6	432
23	Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group. Journal of Clinical Oncology, 2003, 21, 20-27.	0.8	420
24	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. New England Journal of Medicine, 2018, 378, 1211-1223.	13.9	343
25	Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood, 2014, 124, 3829-3830.	0.6	313
26	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discovery, 2019, 9, 342-353.	7.7	306
27	Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2007, 25, 1114-1120.	0.8	289
28	Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncology, The, 2017, 18, 230-240.	5.1	287
29	ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood, 2003, 102, 2568-2573.	0.6	281
30	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood, 2012, 120, 1570-1580.	0.6	268
31	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of Clinical Oncology, 2021, 39, 3441-3452.	0.8	266
32	Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica, 2010, 95, 557-566.	1.7	260
33	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood, 2019, 134, 851-859.	0.6	259
34	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. Journal of Clinical Oncology, 2018, 36, 1973-1980.	0.8	257
35	Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. Journal of Clinical Oncology, 2019, 37, 269-277.	0.8	250
36	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Annals of Oncology, 2017, 28, 1436-1447.	0.6	249

#	Article	IF	Citations
37	Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia, 2010, 24, 1719-1724.	3.3	247
38	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood, 2016, 127, 3215-3224.	0.6	242
39	Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood, 2004, 104, 2926-2932.	0.6	235
40	The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica, 2014, 99, 1107-1113.	1.7	225
41	Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigenâ€“specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood, 2006, 108, 2280-2289.	0.6	215
42	Update on Treatment Recommendations From the Fourth International Workshop on WaldenstrÃ¶m's Macroglobulinemia. Journal of Clinical Oncology, 2009, 27, 120-126.	0.8	207
43	Therapeutic Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Idiopathic Acquired Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 524-531.	2.5	205
44	Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Annals of Oncology, 2008, 19, 233-241.	0.6	203
45	High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood, 2003, 103, 1089-1098.	0.6	201
46	Serological Diagnosis of Idiopathic Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 658-662.	2.5	199
47	Development of Neuropathy in Patients With Myeloma Treated With Thalidomide: Patterns of Occurrence and the Role of Electrophysiologic Monitoring. Journal of Clinical Oncology, 2006, 24, 4507-4514.	0.8	195
48	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood, 2017, 129, 553-560.	0.6	193
49	Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases. Clinical Cancer Research, 2008, 14, 2717-2725.	3.2	182
50	Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood, 2014, 124, 511-518.	0.6	182
51	Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. British Journal of Haematology, 2006, 132, 3-12.	1.2	178
52	Positron Emission Tomographyâ€“Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants. Journal of Clinical Oncology, 2011, 29, 3194-3200.	0.8	176
53	Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. Journal of Clinical Oncology, 2019, 37, 2815-2824.	0.8	173
54	Continued azacitidine therapy beyond time of first response improves quality of response in patients with higherâ€risk myelodysplastic syndromes. Cancer, 2011, 117, 2697-2702.	2.0	169

#	Article	IF	Citations
55	Primary testicular lymphoma. Blood, 2014, 123, 486-493.	0.6	166
56	Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. Journal of Clinical Oncology, 2018, 36, 2395-2404.	0.8	165
57	Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma.. Journal of Clinical Oncology, 1995, 13, 575-582.	0.8	164
58	Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica, 2007, 92, 486-492.	1.7	164
59	Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood, 2008, 112, 3965-3973.	0.6	160
60	Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkinâ€™s disease and non-Hodgkinâ€™s lymphoma. American Journal of Medicine, 2002, 112, 262-268.	0.6	159
61	Durable responses to imatinib in patients with PDGFRB fusion geneâ€“positive and BCR-ABLâ€“negative chronic myeloproliferative disorders. Blood, 2007, 109, 61-64.	0.6	156
62	Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood, 2013, 121, 3818-3824.	0.6	153
63	Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood, 2017, 129, 3362-3370.	0.6	150
64	Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia, 2003, 17, 2401-2409.	3.3	148
65	5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen. Journal of Clinical Oncology, 2009, 27, 5208-5212.	0.8	147
66	Dynamic molecular monitoring reveals that SWIâ€“SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nature Medicine, 2019, 25, 119-129.	15.2	147
67	Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated WaldenstrÃ¶m Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma. Journal of Clinical Oncology, 2013, 31, 301-307.	0.8	146
68	Galectin-1 mediated suppression of Epstein-Barr virusâ€“specific T-cell immunity in classic Hodgkin lymphoma. Blood, 2007, 110, 1326-1329.	0.6	145
69	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood, 2019, 134, 111-122.	0.6	145
70	Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Annals of Oncology, 2015, 26, 1175-1179.	0.6	142
71	Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. Journal of Clinical Oncology, 2016, 34, 2575-2582.	0.8	142
72	Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. Journal of Clinical Oncology, 2020, 38, 4042-4054.	0.8	141

#	Article	IF	Citations
73	Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematology,the, 2015, 2, e357-e366.	2.2	133
74	Treatment of patients with advanced mycosis fungoides and SÃ©zary syndrome with alemtuzumab. European Journal of Haematology, 2003, 71, 250-256.	1.1	132
75	BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria. Clinical Cancer Research, 2007, 13, 7080-7085.	3.2	131
76	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood, 2018, 132, 49-58.	0.6	130
77	Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma. Clinical Cancer Research, 2006, 12, 460-464.	3.2	129
78	Efficacy of Granulocyteâ€“Macrophage Colony-Stimulating Factor in Acquired Alveolar Proteinosis. New England Journal of Medicine, 1996, 335, 1924-1925.	13.9	128
79	The urgent need for integrated science to fight COVID-19 pandemic and beyond. Journal of Translational Medicine, 2020, 18, 205.	1.8	128
80	Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2018, 24, 4371-4379.	3.2	127
81	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2021, 32, 298-308.	0.6	127
82	Calcitriol Production in Hypercalcemic and Normocalcemic Patients with Non-Hodgkin Lymphoma. Annals of Internal Medicine, 1994, 121, 633.	2.0	125
83	Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood, 2002, 99, 4265-4275.	0.6	122
84	Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage Iâ€“II Indolent Non-Hodgkinâ€™s Lymphoma. Journal of Clinical Oncology, 2003, 21, 2115-2122.	0.8	122
85	Impact of [18F] Fluorodeoxyglucose Positron Emission Tomography on Staging and Management of Early-Stage Follicular Non-Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2008, 71, 213-219.	0.4	120
86	A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica, 2013, 98, 1067-1072.	1.7	120
87	Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Annals of Oncology, 2010, 21, 1870-1876.	0.6	119
88	Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood, 2014, 123, 3574-3577.	0.6	118
89	Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood, 2020, 135, 773-777.	0.6	115
90	A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. British Journal of Cancer, 2014, 111, 1072-1079.	2.9	113

#	Article	IF	Citations
91	Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Annals of Oncology, 2004, 15, 1215-1221.	0.6	111
92	Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. European Journal of Haematology, 2010, 85, 130-138.	1.1	111
93	Primary breast lymphoma. Cancer Treatment Reviews, 2014, 40, 900-908.	3.4	109
94	Effects of azacitidine compared with conventional care regimens in elderly (â‰¥75 years) patients with higher-risk myelodysplastic syndromes. Critical Reviews in Oncology/Hematology, 2010, 76, 218-227.	2.0	108
95	Oseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, Australia. Emerging Infectious Diseases, 2010, 16, 1068-1075.	2.0	108
96	Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Annals of Oncology, 2013, 24, 2119-2123.	0.6	107
97	Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood, 2015, 125, 2649-2655.	0.6	107
98	A Randomized, Open-Label, Multicenter Comparative Study of the Efficacy and Safety of Piperacillin-Tazobactam and Cefepime for the Empirical Treatment of Febrile Neutropenic Episodes in Patients with Hematologic Malignancies. Clinical Infectious Diseases, 2006, 43, 447-459.	2.9	106
99	Parathyroid hormoneâ€related protein in hypercalcaemia associated with haematological malignancy. British Journal of Haematology, 1996, 94, 486-492.	1.2	104
100	Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. American Journal of Hematology, 2004, 77, 72-76.	2.0	104
101	The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. European Journal of Haematology, 2006, 76, 473-480.	1.1	104
102	Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, v91-v102.	0.6	102
103	Adolescent and young adult cancer: a revolution in evolution?. Internal Medicine Journal, 2006, 36, 302-307.	0.5	101
104	Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia, 2018, 32, 2546-2557.	3.3	101
105	Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia, 2010, 24, 2056-2062.	3.3	99
106	Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 2008, 112, 325-325.	0.6	99
107	Prognostic Value of Serum Interleukin-6 in Diffuse Large-cell Lymphoma. Annals of Internal Medicine, 1997, 127, 186.	2.0	98
108	Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leukemia Research, 2009, 33, 861-864.	0.4	97

#	Article	IF	Citations
109	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematology,the, 2018, 5, e563-e598.	2.2	97
110	The addition of rituximab to anthracyclineâ€based chemotherapy significantly improves outcome in â€˜Westernâ€™ patients with intravascular large Bâ€cell lymphoma. British Journal of Haematology, 2008, 143, 253-257.	1.2	96
111	A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Annals of Oncology, 2008, 19, 247-253.	0.6	92
112	The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia, 2009, 23, 2034-2041.	3.3	91
113	Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield. British Journal of Cancer, 2006, 94, 1007-1010.	2.9	90
114	Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. Annals of Oncology, 2009, 20, 1993-1999.	0.6	90
115	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. European Journal of Cancer, 2018, 93, 57-68.	1.3	90
116	The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial. Blood, 2015, 126, 832-832.	0.6	90
117	Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Thorax, 2003, 58, 252-257.	2.7	89
118	Multicenter Phase II Clinical Study of Iodine-131â€“Rituximab Radioimmunotherapy in Relapsed or Refractory Indolent Non-Hodgkinâ€™s Lymphoma. Journal of Clinical Oncology, 2006, 24, 4418-4425.	0.8	89
119	Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-hodgkin lymphoma. Cancer, 2006, 106, 2412-2420.	2.0	85
120	Pulmonary alveolar proteinosis. Clinics in Chest Medicine, 2004, 25, 593-613.	0.8	83
121	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the <scp>BCL</scp>2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory <scp>CD</scp>20⁺ lymphoid malignancies. British Journal of Haematology, 2015, 170, 669-678.	1.2	80
122	R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica, 2014, 99, 1343-1349.	1.7	79
123	BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF. Thorax, 2002, 57, 277-280.	2.7	78
124	Frequent Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography on the Staging and Management of Patients with Indolent Non-Hodgkin's Lymphoma. Clinical Lymphoma and Myeloma, 2003, 4, 43-49.	2.1	78
125	Initial Staging of Lymphoma With Positron Emission Tomography and Computed Tomography. Seminars in Nuclear Medicine, 2005, 35, 165-175.	2.5	78
126	Zanubrutinib for the treatment of patients with WaldenstrÃ¶m macroglobulinemia: 3 years of follow-up. Blood, 2020, 136, 2027-2037.	0.6	78

#	Article	IF	Citations
127	Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. European Journal of Haematology, 2007, 79, 226-233.	1.1	77
128	Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices. Supportive Care in Cancer, 2009, 17, 811-818.	1.0	76
129	Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03. Journal of Clinical Oncology, 2018, 36, 2918-2925.	0.8	76
130	Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Annals of Oncology, 2013, 24, 1344-1351.	0.6	75
131	Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematology,the, 2015, 2, e445-e455.	2.2	74
132	Clinical Correlates of Elevated Serum Levels of Interleukin-6 in Patients with Untreated Hodgkin's Disease. American Journal of Medicine, 1997, 102, 21-28.	0.6	72
133	Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-Î±-resistant hairy cell leukemia: 7-year follow-up. Leukemia, 1997, 11, 42-47.	3.3	72
134	Primary Large-Cell Non-Hodgkin's Lymphoma of the Testis: A Retrospective Analysis of Patterns of Failure and Prognostic Factors. Clinical Lymphoma and Myeloma, 2001, 2, 109-115.	2.1	72
135	Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative preâ€transplant FDGâ€PET scan following salvage chemotherapy. British Journal of Haematology, 2010, 150, 39-45.	1.2	72
136	Oligospermia in a Patient Receiving Imatinib Therapy for the Hypereosinophilic Syndrome. New England Journal of Medicine, 2004, 351, 2134-2135.	13.9	71
137	Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging, 2007, 7, 10-18.	1.2	71
138	An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. British Journal of Cancer, 2005, 92, 867-872.	2.9	70
139	Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. Nature Communications, 2017, 8, 14756.	5.8	70
140	BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood, 2020, 135, 2266-2270.	0.6	67
141	Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leukemia and Lymphoma, 2013, 54, 472-475.	0.6	66
142	Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia, 2018, 32, 2572-2579.	3.3	66
143	Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy. Blood, 2013, 122, 509-509.	0.6	66
144	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. European Journal of Cancer, 2017, 75, 195-203.	1.3	65

#	Article	IF	Citations
145	Limited role for surveillance PETâ€“CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. British Journal of Cancer, 2013, 109, 312-317.	2.9	64
146	Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica, 2019, 104, 1202-1208.	1.7	64
147	The hyper-CVADâ€“rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Annals of Hematology, 2006, 86, 101-105.	0.8	63
148	Functional Reversion of Antigen-Specific CD8+ T Cells from Patients with Hodgkin Lymphoma following In Vitro Stimulation with Recombinant Polyepitope. Journal of Immunology, 2006, 177, 4897-4906.	0.4	63
149	Mice Lacking Three Myeloid Colony-Stimulating Factors (G-CSF, GM-CSF, and M-CSF) Still Produce Macrophages and Granulocytes and Mount an Inflammatory Response in a Sterile Model of Peritonitis. Journal of Immunology, 2007, 178, 6435-6443.	0.4	62
150	Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood, 1993, 82, 1383-94.	0.6	62
151	Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography Before and After Definitive Radiation Therapy in Patients With Apparently Solitary Plasmacytoma. International Journal of Radiation Oncology Biology Physics, 2009, 74, 740-746.	0.4	61
152	Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Annals of Oncology, 2018, 29, 1822-1827.	0.6	61
153	Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. Journal of Clinical Oncology, 2020, 38, 2971-2980.	0.8	61
154	A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. Blood, 2015, 126, 254-254.	0.6	61
155	Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leukemia and Lymphoma, 2005, 46, 1575-1579.	0.6	60
156	Intrathecal Chemotherapy alone is Inadequate Central Nervous System Prophylaxis in Patients with Intermediate-grade Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2002, 43, 1783-1788.	0.6	59
157	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patientâ€“Level Analysis of Multiple Randomized Trials (SEAL). Journal of Clinical Oncology, 2018, 36, 2593-2602.	0.8	59
158	Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplantation, 2001, 28, 101-103.	1.3	58
159	Recommendations for the treatment of established fungal infections. Internal Medicine Journal, 2008, 38, 496-520.	0.5	58
160	Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica, 2012, 97, 227-234.	1.7	57
161	A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer Journal, 2014, 4, e238-e238.	2.8	57
162	Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. BMC Cancer, 2017, 17, 852.	1.1	57

#	Article	IF	Citations
163	Mice lacking both granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF have impaired reproductive capacity, perturbed neonatal granulopoiesis, lung disease, amyloidosis, and reduced long-term survival. Blood, 1997, 90, 3037-49.	0.6	57
164	Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood, 2012, 120, 2650-2657.	0.6	56
165	Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 4527-4533.	3.2	56
166	The landscape of new drugs in lymphoma. Nature Reviews Clinical Oncology, 2017, 14, 335-346.	12.5	56
167	Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica, 2006, 91, 1546-50.	1.7	56
168	Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood, 2022, 140, 839-850.	0.6	55
169	Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies. Diagnostic Microbiology and Infectious Disease, 2014, 79, 322-327.	0.8	54
170	Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis. Blood, 2011, 118, 282-282.	0.6	54
171	Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica, 2017, 102, 356-363.	1.7	53
172	Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica, 2005, 90, 1672-9.	1.7	53
173	Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. Bone Marrow Transplantation, 1999, 23, 107-110.	1.3	52
174	Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma. Annals of Oncology, 2003, 14, 273-276.	0.6	52
175	A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. European Journal of Haematology, 2004, 72, 32-37.	1.1	52
176	Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Annals of Oncology, 2012, 23, 1259-1266.	0.6	51
177	Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan. BMC Pulmonary Medicine, 2014, 14, 37.	0.8	51
178	A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research, 2005, 11, 5504-5514.	3.2	50
179	Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. British Journal of Haematology, 2009, 147, 83-88.	1.2	50
180	Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematology,the, 2019, 6, e366-e374.	2.2	49

#	Article	IF	Citations
181	Case/control study of the role of splenectomy in chronic lymphocytic leukemia.. Journal of Clinical Oncology, 1997, 15, 52-60.	0.8	48
182	A â‰¥1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. Leukemia and Lymphoma, 2008, 49, 517-523.	0.6	48
183	Guidelines for the use of antifungal agents in the treatment of invasiveCandidaand mould infections. Internal Medicine Journal, 2004, 34, 192-200.	0.5	46
184	Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. International Journal of Molecular Sciences, 2017, 18, 415.	1.8	45
185	Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia, 2003, 17, 821-828.	3.3	44
186	Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Internal Medicine Journal, 2009, 39, 304-316.	0.5	44
187	Distress and unmet needs during treatment and quality of life in early cancer survivorship: A longitudinal study of haematological cancer patients. European Journal of Haematology, 2017, 99, 423-430.	1.1	43
188	The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Annals of Oncology, 2010, 21, 331-334.	0.6	42
189	Azacitidine in adult patients with acute myeloid leukemia. Critical Reviews in Oncology/Hematology, 2017, 116, 159-177.	2.0	42
190	ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.. Journal of Clinical Oncology, 2014, 32, 7015-7015.	0.8	42
191	Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature. Cancer Genetics and Cytogenetics, 2006, 171, 52-56.	1.0	41
192	Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3887-3893.	1.8	41
193	Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine. Leukemia, 2004, 18, 1034-1038.	3.3	40
194	A denileukin diftitox (Ontak) associated retinopathy?. British Journal of Ophthalmology, 2006, 90, 1070-1071.	2.1	40
195	Role of Arsenic Trioxide in Acute Promyelocytic Leukemia. Current Treatment Options in Oncology, 2013, 14, 170-184.	1.3	40
196	Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study. Blood, 2016, 128, 6-6.	0.6	40
197	Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.. Journal of Clinical Oncology, 2014, 32, 8522-8522.	0.8	40
198	Carbamazepine Overdose. Drug Safety, 1993, 8, 81-88.	1.4	39

#	Article	IF	Citations
199	Regression of Gastric Lymphoma with Therapy for Helicobacter pylori Infection. Annals of Internal Medicine, 1997, 127, 247.	2.0	39
200	Detection of NPM1 exon 12 mutations and FLT3 â€“ internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia. Journal of Hematology and Oncology, 2008, 1, 10.	6.9	39
201	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Advances, 2021, 5, 4054-4058.	2.5	39
202	[18F]Fluorodeoxyglucose Positron Emission Tomography Scanning for Staging, Response Assessment, and Disease Surveillance in Patients with Mantle Cell Lymphoma. Clinical Lymphoma and Myeloma, 2008, 8, 159-165.	1.4	38
203	The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma. Clinical and Experimental Immunology, 2016, 183, 206-220.	1.1	38
204	Long-term Follow-up of Patients with Relapsed or Refractory Nonâ€“Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. Clinical Cancer Research, 2021, 27, 4690-4695.	3.2	38
205	Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study. Blood, 2015, 126, 830-830.	0.6	38
206	Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy.. Journal of Clinical Oncology, 2010, 28, 8004-8004.	0.8	38
207	Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia, 1995, 9, 929-32.	3.3	38
208	2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood, 1994, 83, 2906-11.	0.6	38
209	Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. British Journal of Haematology, 2019, 186, e188-e191.	1.2	37
210	Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma. Haematologica, 2020, 105, e76-e79.	1.7	37
211	Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx). Blood, 2020, 136, 19-21.	0.6	37
212	Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy. Leukemia, 1999, 13, 1735-1740.	3.3	36
213	Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. Lancet Haematology,the, 2015, 2, e166-e174.	2.2	36
214	Cure of Pulmonary Rhizomucor Pusillus Infection in a Patient with Hairy-Cell Leukemia: Role of Liposomal Amphotericin B and GM-CSF. Leukemia and Lymphoma, 2001, 42, 1393-1399.	0.6	35
215	Fludarabine Combination Therapy Is Highly Effective in First-Line and Salvage Treatment of Patients with WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2005, 6, 136-139.	1.4	35
216	Treatment of chronic myelomonocytic leukemia with azacitidine. Leukemia and Lymphoma, 2013, 54, 878-880.	0.6	35

#	Article	IF	Citations
217	Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms. Epigenomics, 2016, 8, 55-66.	1.0	35
218	Role of 18 FDG-positron Emission Tomography Scanning in the Management of Histiocytosis. Leukemia and Lymphoma, 2002, 43, 2155-2157.	0.6	34
219	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large Bâ€cell lymphoma is associated with poor outcomes and a high frequency of secondary <scp>CNS</scp> involvement. British Journal of Haematology, 2016, 175, 876-883.	1.2	34
220	Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. Blood Advances, 2020, 4, 165-173.	2.5	34
221	First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.. Journal of Clinical Oncology, 2021, 39, 7500-7500.	0.8	34
222	Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. Blood, 2022, 139, 1198-1207.	0.6	34
223	Sequential Cis-Platinum and Fludarabine with or without Arabinosyl Cytosine in Patients Failing Prior Fludarabine Therapy for Chronic Lymphocytic Leukemia: A Phase II Study. Leukemia and Lymphoma, 1999, 36, 57-65.	0.6	33
224	Diffuse Large Cell Lymphoma and t(8;22) (q24;q11) in a Patient with Idiopathic CD4+ T-Lymphopenia. Leukemia and Lymphoma, 2001, 41, 421-423.	0.6	33
225	Primary Non-Hodgkin's Lymphoma of the Breast: Retrospective Analysis of Prognosis and Patterns of Failure in Two Australian Centers. Clinical Lymphoma and Myeloma, 2006, 6, 337-341.	1.4	33
226	The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers. Supportive Care in Cancer, 2017, 25, 3447-3456.	1.0	33
227	BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib. Blood, 2019, 134, 170-170.	0.6	33
228	The prognostic significance of auer rods in myelodysplasia. British Journal of Haematology, 1993, 85, 67-76.	1.2	32
229	Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. British Journal of Haematology, 2005, 130, 87-91.	1.2	32
230	A new prognostic score for CLL. Blood, 2014, 124, 1-2.	0.6	32
231	Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. Leukemia and Lymphoma, 2017, 58, 2811-2814.	0.6	32
232	A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies. Cancer, 2004, 101, 2042-2049.	2.0	31
233	Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1348-1355.	3.3	31
234	Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study. Palliative and Supportive Care, 2015, 13, 255-263.	0.6	31

#	Article	IF	Citations
235	Cisplatin, fludarabine, and cytarabine. Cancer, 2002, 94, 585-593.	2.0	30
236	Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leukemia and Lymphoma, 2005, 46, 549-552.	0.6	30
237	Early therapeutic response assessment by18FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leukemia and Lymphoma, 2007, 48, 596-600.	0.6	30
238	Epidemiology of invasive fungal disease in lymphoproliferative disorders. Haematologica, 2015, 100, e462-e466.	1.7	30
239	Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit. Journal of Antimicrobial Chemotherapy, 2016, 71, 497-505.	1.3	30
240	Patient perceptions of treatment-free remission in chronic myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 406-415.	0.6	30
241	Fertility preservation in female oncology patients. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2006, 46, 15-23.	0.4	29
242	Acute Leukemia Complicating Bone Marrow Hypoplasia in an Adult with Shwachman's Syndrome. Leukemia and Lymphoma, 1993, 12, 131-135.	0.6	28
243	Fludarabine and mitoxantrone: Effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Annals of Oncology, 2001, 12, 1455-1460.	0.6	28
244	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. Leukemia, 2021, 35, 1864-1872.	3.3	28
245	Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy. Blood, 2022, 140, 2127-2141.	0.6	28
246	Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment. Annals of Oncology, 2002, 13, 327-330.	0.6	27
247	Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Internal Medicine Journal, 2011, 41, 75-81.	0.5	27
248	Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency. Acta Haematologica, 2013, 130, 254-259.	0.7	27
249	Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. Blood, 2021, 138, 836-846.	0.6	27
250	High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. Annals of Oncology, 1996, 7, 157-163.	0.6	26
251	Deafness from eighth cranial nerve involvement in a patient with large-cell transformation of mycosis fungoides. European Journal of Haematology, 2000, 64, 340-343.	1.1	26
252	Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease: diagnostic dilemmas and management options. Annals of Hematology, 2005, 84, 118-121.	0.8	26

#	Article	IF	Citations
253	JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias. Genes and Development, 2018, 32, 849-864.	2.7	26
254	Follicular Lymphoma Evaluation Index (<scp>FLEX</scp>): A new clinical prognostic model that is superior to existing risk scores for predicting progressionâ€free survival and early treatment failure after frontline immunochemotherapy. American Journal of Hematology, 2020, 95, 1503-1510.	2.0	26
255	Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment. JMIR MHealth and UHealth, 2017, 5, e184.	1.8	26
256	Survival of Young Patients with Chronic Lymphocytic Leukemia Failing Fludarabine Therapy: A Basis for the Use of Myeloablative Therapies. Leukemia and Lymphoma, 1995, 18, 493-496.	0.6	25
257	Graft versus Burkitt's Lymphoma Effect after Allogeneic Marrow Transplantation. Leukemia and Lymphoma, 2002, 43, 889-891.	0.6	25
258	Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies. Cancer, 2004, 100, 2181-2189.	2.0	25
259	Complete molecular response of e6a2 BCR-ABLâ€“positive acute myeloid leukemia to imatinib then dasatinib. Blood, 2008, 111, 2896-2898.	0.6	25
260	The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period. Journal of Cancer Survivorship, 2017, 11, 329-338.	1.5	25
261	Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A. Mycoses, 2007, 50, 24-37.	1.8	24
262	Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target. Leukemia and Lymphoma, 2015, 56, 3250-3256.	0.6	24
263	The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica, 2016, 101, 235-240.	1.7	24
264	Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. Blood, 2019, 134, 756-756.	0.6	24
265	Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination. Journal of Hematology and Oncology, 2022, 15, .	6.9	24
266	Lateâ€onset <scp>P</scp>neumocystis jirovecii pneumonia postâ€“fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. European Journal of Haematology, 2013, 91, 157-163.	1.1	23
267	Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). Blood, 2016, 128, 642-642.	0.6	23
268	Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica, 2005, 90, 700-2.	1.7	23
269	Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leukemia and Lymphoma, 2006, 47, 1813-1817.	0.6	22
270	An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009. Internal Medicine Journal, 2011, 41, 110-120.	0.5	22

#	Article	IF	Citations
271	The molecular pathogenesis of Bâ€cell nonâ€Hodgkin lymphoma. European Journal of Haematology, 2015, 95, 280-293.	1.1	22
272	Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. Journal of Clinical Oncology, 2018, 36, 3525-3527.	0.8	22
273	High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management. Journal of Clinical Oncology, 2020, 38, 4302-4316.	0.8	22
274	Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Advances, 2022, 6, 4553-4557.	2.5	22
275	Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. Blood, 2022, 140, 1907-1916.	0.6	22
276	Early B-cell chronic lymphocytic leukemia presenting as cutaneous lesions with a normal peripheral blood lymphocyte count. Journal of the American Academy of Dermatology, 2005, 53, 534-535.	0.6	21
277	Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells. Bone Marrow Transplantation, 2013, 48, 351-356.	1.3	21
278	Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes. Leukemia and Lymphoma, 2017, 58, 2379-2386.	0.6	21
279	The Contribution of Auer Rods to the Classification and Prognosis of Myelodysplastic Syndromes. Leukemia and Lymphoma, 1995, 17, 79-85.	0.6	20
280	Cardiac involvement in Henoch-Schonlein purpura. Internal Medicine Journal, 2006, 36, 328-331.	0.5	20
281	A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment. Australian Health Review, 2011, 35, 491.	0.5	20
282	The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS). Blood, 2008, 112, 227-227.	0.6	20
283	The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function. Leukemia Research, 2006, 30, 483-485.	0.4	19
284	The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. Hematological Oncology, 2006, 24, 159-163.	0.8	19
285	Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study. Leukemia and Lymphoma, 2009, 50, 211-215.	0.6	19
286	Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy. Journal of Antimicrobial Chemotherapy, 2013, 68, 1669-1678.	1.3	19
287	Central Nervous System Prophylaxis in Non-Hodgkin Lymphoma: Who, What, and When?. Current Oncology Reports, 2015, 17, 25.	1.8	19
288	Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience. Journal of Antimicrobial Chemotherapy, 2016, 71, 3540-3547.	1.3	19

#	Article	IF	Citations
289	Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2013, 31, 7018-7018.	0.8	19
290	Progressive Multifocal Leukoencephalopathy Complicating WaldenstrÃ¶m's Macroglobulinaemia. Leukemia and Lymphoma, 2003, 44, 1819-1821.	0.6	18
291	Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Bone Marrow Transplantation, 2011, 46, 764-765.	1.3	18
292	A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia. British Journal of Haematology, 2014, 167, 618-625.	1.2	18
293	Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy. Annals of Hematology, 2014, 93, 1193-1200.	0.8	18
294	Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial. Blood, 2019, 134, 500-500.	0.6	18
295	A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. Leukemia and Lymphoma, 2005, 46, 197-206.	0.6	17
296	Extra-pulmonary aspects of acquired pulmonary alveolar proteinosis as predicted by granulocyte-macrophage colony-stimulating factor-deficient mice. Respirology, 2006, 11, S16-S22.	1.3	17
297	High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1330-1336.	3.3	17
298	Effective mitigation of tumor lysis syndrome with gradual venetoclax dose ramp, prophylaxis, and monitoring in patients with chronic lymphocytic leukemia. Annals of Hematology, 2016, 95, 1361-1362.	0.8	17
299	Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia. Seminars in Oncology, 2016, 43, 274-279.	0.8	17
300	Diffuse Large B-cell Non-Hodgkin's Lymphoma Presenting as Sister Joseph's Nodule. Leukemia and Lymphoma, 2002, 43, 2055-2057.	0.6	16
301	New Treatment Approaches To Indolent Non-Hodgkinâ€™s Lymphoma. Seminars in Oncology, 2004, 31, 27-32.	0.8	16
302	Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator. Leukemia, 2009, 23, 305-312.	3.3	16
303	Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2010, 51, 2188-2197.	0.6	16
304	Challenges and Outcomes of a Randomized Study of Early Nutrition Support during Autologous Stem-Cell Transplantation. Current Oncology, 2014, 21, 334-339.	0.9	16
305	Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 1813-1818.	2.0	16
306	The utility and limitations of18F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. Leukemia and Lymphoma, 2015, 56, 49-56.	0.6	16

#	Article	IF	Citations
307	Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 2019, 134, 355-355.	0.6	16
308	Single-cell sequencing demonstrates complex resistance landscape inÂCLL and MCL treated with BTK and BCL2 inhibitors. Blood Advances, 2022, 6, 503-508.	2.5	16
309	Docetaxel effectively mobilizes peripheral blood CD34+ cells. Bone Marrow Transplantation, 2000, 26, 483-487.	1.3	15
310	Successful Treatment of Rhinocerebral Zygomycosis Using Liposomal Nystatin. Leukemia and Lymphoma, 2001, 42, 1119-1123.	0.6	15
311	A Phase Ib Clinical Trial of PV701, a Milk-Derived Protein Extract, for the Prevention and Treatment of Oral Mucositis in Patients Undergoing High-Dose BEAM Chemotherapy. Biology of Blood and Marrow Transplantation, 2005, 11, 512-520.	2.0	15
312	Phase III Study of Chlorambucil Versus Fludarabine as Initial Therapy for WaldenstrÃ¶m's Macroglobulinemia and Related Disorders. Clinical Lymphoma and Myeloma, 2005, 5, 294-297.	2.1	15
313	Primary skeletal muscle marginal zone lymphoma with persistent tissue tropism and PET-avidity. Leukemia and Lymphoma, 2006, 47, 117-120.	0.6	15
314	Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients. Annals of Hematology, 2008, 87, 727-734.	0.8	15
315	Surveillance for Catheter-Associated Bloodstream Infection in Hematology Units: Quantifying the Characteristics of a Practical Case Definition. Infection Control and Hospital Epidemiology, 2008, 29, 358-360.	1.0	15
316	Paraneoplastic large vessel arteritis complicating myelodysplastic syndrome. Leukemia and Lymphoma, 2012, 53, 1613-1616.	0.6	15
317	Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era. Blood Reviews, 2017, 31, 318-327.	2.8	15
318	Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study. Blood, 2020, 136, 44-45.	0.6	15
319	Refractory Chronic Lymphocytic Leukemia Complicated by Hypercalcemia Treated with Allogeneic Bone Marrow Transplantation. American Journal of Clinical Oncology: Cancer Clinical Trials, 1994, 17, 360.	0.6	14
320	Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: Results of a phase I study. Annals of Oncology, 1999, 10, 479-481.	0.6	14
321	Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and SÃ©zary syndrome. European Journal of Haematology, 2004, 73, 447-449.	1.1	14
322	Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib. Leukemia Research, 2008, 32, 1789-1790.	0.4	14
323	Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamideÂ±rituximab. Leukemia and Lymphoma, 2009, 50, 463-465.	0.6	14
324	ABVD versus BEACOPP for Hodgkin's Lymphoma. New England Journal of Medicine, 2011, 365, 1544-1546.	13.9	14

#	Article	IF	Citations
325	When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?. Internal Medicine Journal, 2012, 42, 450-455.	0.5	14
326	Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. Journal of Clinical Oncology, 2017, 35, 1678-1685.	0.8	14
327	Better Sepsis Management Rather Than Fluoroquinolone Prophylaxis for Patients With Cancer-Related Immunosuppression. Journal of Clinical Oncology, 2019, 37, 1139-1140.	0.8	14
328	Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. Haematologica, 2019, 104, 700-709.	1.7	14
329	Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. Blood Advances, 2020, 4, 4849-4859.	2.5	14
330	Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. Blood, 2017, 130, LBA-2-LBA-2.	0.6	14
331	Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. Leukemia and Lymphoma, 2013, 54, 1465-1472.	0.6	13
332	Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance. Leukemia and Lymphoma, 2014, 55, 938-939.	0.6	13
333	Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care. Best Practice and Research in Clinical Haematology, 2014, 27, 39-52.	0.7	13
334	Outcome of patients with early-stage follicular lymphoma staged with 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 80-86.	3.3	13
335	How I treat chronic lymphocytic leukemia after venetoclax. Blood, 2021, 138, 361-369.	0.6	13
336	Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study. Blood, 2020, 136, 45-47.	0.6	13
337	Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study. Blood, 2015, 126, LBA-6-LBA-6.	0.6	13
338	Bilateral fracture of the mandible in chronic lymphocytic leukaemia. Case report. Australian Dental Journal, 1997, 42, 20-24.	0.6	12
339	â€˜Miniâ€allograftsâ€™ for haematological malignancies: an alternative to conventional myeloablative marrow transplantation. Australian and New Zealand Journal of Medicine, 1999, 29, 308-314.	0.5	12
340	Severe respiratory syncytial virus pneumonia complicating fludarabine and cyclophosphamide treatment of chronic lymphocytic leukemia. European Journal of Haematology, 2002, 69, 54-57.	1.1	12
341	Lack of apoptosis of Sezary cells in the circulation following oral bexarotene therapy. British Journal of Dermatology, 2005, 152, 1199-1205.	1.4	12
342	The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders. Cancer, 2006, 107, 773-780.	2.0	12

#	Article	IF	Citations
343	Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab. Annals of Oncology, 2008, 19, 1629-1633.	0.6	12
344	The Choice of Multiple Myeloma Induction Therapy Affects the Frequency and Severity of Oral Mucositis After Melphalan-Based Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 291-296.	0.2	12
345	How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?. Leukemia and Lymphoma, 2015, 56, 1599-1610.	0.6	12
346	Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). Leukemia and Lymphoma, 2017, 58, 298-307.	0.6	12
347	Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with <scp>BCR</scp> signalling inhibitors. British Journal of Haematology, 2017, 177, 324-328.	1.2	12
348	Venetoclaxâ€“Rituximab in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2018, 378, 2141-2144.	13.9	12
349	Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood, 2016, 128, 3230-3230.	0.6	12
350	ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.. Journal of Clinical Oncology, 2014, 32, 7013-7013.	0.8	12
351	Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study. Bone Marrow Transplantation, 2000, 26, 955-961.	1.3	11
352	Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy. Cytotherapy, 2002, 4, 137-145.	0.3	11
353	The effects of continued azacitidine treatment cycles on response in higher-risk patients with myelodysplastic syndromes: An update. Ecancermedicalscience, 2009, 3, 118.	0.6	11
354	The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution. Expert Opinion on Biological Therapy, 2010, 10, 113-125.	1.4	11
355	Liver Transplantation in an Adult With Sclerosing Cholangitis due to Multisystem Langerhans Cell Histiocytosis. American Journal of Transplantation, 2011, 11, 1755-1756.	2.6	11
356	Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma. Blood, 2014, 123, 2740-2742.	0.6	11
357	Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial. Bone Marrow Transplantation, 2014, 49, 1056-1062.	1.3	11
358	Pneumocystis jiroveciipneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis. Leukemia and Lymphoma, 2015, 56, 157-162.	0.6	11
359	Follicular lymphoma: Stateâ€ofâ€theâ€art ICML workshop in Lugano 2015. Hematological Oncology, 2017, 35, 397-407.	0.8	11
360	A Retrospective Evaluation of Risk of Peripartum Cardiac Dysfunction in Survivors of Childhood, Adolescent and Young Adult Malignancies. Cancers, 2019, 11, 1046.	1.7	11

#	Article	IF	Citations
361	Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial. Blood, 2014, 124, 10-10.	0.6	11
362	The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: <i>post-hoc</i> analyses from the phase III MURANO study. Haematologica, 2022, 107, 134-142.	1.7	11
363	Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: â€œWhat's Past Is Prologueâ€• (Shakespeare). Clinical Cancer Research, 2022, 28, 603-608.	3.2	11
364	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematology,the, 2022, 9, e374-e384.	2.2	11
365	Induction of hypomagnesemia during amsacrine treatment. American Journal of Hematology, 1993, 42, 262-267.	2.0	10
366	Discordant Response to Chemotherapy Detected by PET Scanning. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 368-370.	0.6	10
367	CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy. Cytotherapy, 2002, 4, 147-155.	0.3	10
368	Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: Role of rituximab, high-dose therapy, and allogeneic stem cell transplantation. Leukemia and Lymphoma, 2005, 46, 1075-1079.	0.6	10
369	Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase. Leukemia and Lymphoma, 2006, 47, 1069-1081.	0.6	10
370	A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma. Leukemia and Lymphoma, 2008, 49, 924-931.	0.6	10
371	Azacitidine prolongs overall survival and reduces infections and hospitalisations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: An update. Ecancermedicalscience, 2009, 3, 121.	0.6	10
372	HLA class I associations with EBV+ post-transplant lymphoproliferative disorder. Transplant Immunology, 2015, 32, 126-130.	0.6	10
373	When to treat patients with relapsed follicular lymphoma. Expert Review of Hematology, 2017, 10, 187-191.	1.0	10
374	Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study. Clinical Pharmacokinetics, 2019, 58, 1621-1634.	1.6	10
375	Abscopal Regressions of Lymphoma After Involved-Site Radiation Therapy Confirmed by Positron Emission Tomography. International Journal of Radiation Oncology Biology Physics, 2020, 108, 204-211.	0.4	10
376	Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.. Blood, 2009, 114, 1755-1755.	0.6	10
377	Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction. Blood, 2013, 122, 1304-1304.	0.6	10
378	Management of localized low-grade follicular lymphomas. Journal of Medical Imaging and Radiation Oncology, 2001, 45, 326-334.	0.6	9

#	Article	IF	Citations
379	Ante-mortem diagnosis of localized invasive esophageal aspergillosis in a patient with acute myeloid leukemia. Leukemia and Lymphoma, 2005, 46, 603-605.	0.6	9
380	Predicting durable remissions following thalidomide therapy for relapsed myeloma. Leukemia and Lymphoma, 2009, 50, 223-229.	0.6	9
381	Phase II study of autologous stem cell transplant using busulfanâ€“melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma. Leukemia and Lymphoma, 2010, 51, 641-649.	0.6	9
382	X. Extraâ€nodal lymphoma in rare localisations: bone, breast and testes. Hematological Oncology, 2013, 31, 60-63.	0.8	9
383	Myeloma and pregnancy: strange bedfellows?. Leukemia and Lymphoma, 2014, 55, 966-968.	0.6	9
384	Prognostic impact of monocyte count at presentation in mantle cell lymphoma. British Journal of Haematology, 2014, 164, 890-893.	1.2	9
385	Optimal approach for high-risk acute promyelocytic leukemia. Current Opinion in Hematology, 2014, 21, 102-113.	1.2	9
386	Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia. British Journal of Haematology, 2017, 176, 829-831.	1.2	9
387	Highâ€dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2017, 178, 991-994.	1.2	9
388	A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation. Blood, 2019, 134, 4318-4318.	0.6	9
389	Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL. Blood, 2019, 134, 3036-3036.	0.6	9
390	Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.. Blood, 2007, 110, 1167-1167.	0.6	9
391	The Addition of Rituximab to Fludarabine and Cyclophosphamide (FC) Improves Overall Survival in Newly Diagnosed Mantle Cell Lymphoma (MCL): Results of the Randomised UK National Cancer Research Institute (NCRI) Trial. Blood, 2011, 118, 440-440.	0.6	9
392	High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study. Blood, 2016, 128, 1216-1216.	0.6	9
393	The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study.. Journal of Clinical Oncology, 2016, 34, 7548-7548.	0.8	9
394	Ovarian tissue cryopreservation for cancer patients: who is appropriate?. Reproduction, Fertility and Development, 2001, 13, 81.	0.1	8
395	Pulmonary Alveolar Proteinosis. Treatments in Respiratory Medicine, 2004, 3, 229-234.	1.4	8
396	Progress in primary CNS lymphoma. Lancet, The, 2009, 374, 1477-1478.	6.3	8

#	Article	IF	Citations
397	Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge. Leukemia and Lymphoma, 2010, 51, 1592-1595.	0.6	8
398	Utility of a clinical risk score to identify highâ€risk patients with de novo acute myeloid leukaemia in first remission after highâ€dose cytarabine (Hi<scp>DAC</scp>) based induction chemotherapy. British Journal of Haematology, 2013, 160, 861-863.	1.2	8
399	Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. British Journal of Haematology, 2014, 165, 49-56.	1.2	8
400	Immunochemotherapy in WaldenstrÃ¶m macroglobulinemia â€“ still the backbone of treatment. Leukemia and Lymphoma, 2015, 56, 2489-2490.	0.6	8
401	Transformed Lymphoma. Hematology/Oncology Clinics of North America, 2016, 30, 1317-1332.	0.9	8
402	Disseminated visceral varicella zoster virus presenting with the constellation of colonic pseudoâ€obstruction, acalculous cholecystitis and syndrome of inappropriate ADH secretion. Internal Medicine Journal, 2016, 46, 238-239.	0.5	8
403	A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. Leukemia and Lymphoma, 2019, 60, 904-911.	0.6	8
404	BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 267-278.e10.	0.2	8
405	Relapsed/Refractory International Prognostic Index (R/<scp>Râ€IPI</scp>): An international prognostic calculator for relapsed/refractory diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2021, 96, 599-605.	2.0	8
406	Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target. British Journal of Haematology, 2021, 195, 113-118.	1.2	8
407	Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?. Hematology/Oncology Clinics of North America, 2021, 35, 775-791.	0.9	8
408	MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 184-184.	0.6	8
409	Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.. Blood, 2005, 106, 164-164.	0.6	8
410	Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study. Blood, 2014, 124, 621-621.	0.6	8
411	Mental neuropathy (Numb Chin syndrome): A harbinger of tumor progression or relapse case reports. Cancer, 1993, 71, 874-875.	2.0	7
412	PARATHYROID HORMONE RELATED PROTEIN IN HYPERCALCAEMIA IN CLL. British Journal of Haematology, 1995, 89, 685-686.	1.2	7
413	A Case of Clinical Indolent Natural Killer Cell Lineage Large Granular Lymphocytic Leukemia in a Patient with Rheumatoid Arthritis. Leukemia and Lymphoma, 2003, 44, 1223-1227.	0.6	7
414	Leukaemic Subtype of Marginal Zone Lymphoma: A Presentation of Three Cases and Literature Review. Leukemia and Lymphoma, 2004, 45, 705-710.	0.6	7

#	Article	IF	Citations
415	Radiotherapy for low-grade gastric marginal zone lymphoma: a retrospective study. Internal Medicine Journal, 2007, 37, 172-180.	0.5	7
416	Negative selection of chronic lymphocytic leukaemia cells using a bifunctional rosette-based antibody cocktail. BMC Biotechnology, 2008, 8, 6.	1.7	7
417	What is the real risk of central nervous system involvement in mantle cell lymphoma?. Leukemia and Lymphoma, 2008, 49, 2237-2239.	0.6	7
418	Fludarabine combinations for patients with advanced marginal zone lymphomas â€“ best treatment option or too toxic?. British Journal of Haematology, 2009, 146, 685-686.	1.2	7
419	The trials and tribulations of conducting an m-health pilot randomized controlled trial to improve oral cancer therapy adherence: recommendations for future multisite, non-drug clinical trials. BMC Research Notes, 2019, 12, 226.	0.6	7
420	Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with firstâ€line immunochemotherapy. British Journal of Clinical Pharmacology, 2019, 85, 1495-1506.	1.1	7
421	Exposureâ€“response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study. Leukemia and Lymphoma, 2020, 61, 56-65.	0.6	7
422	Autologous stem cell transplantation for untreated transformed indolent Bâ€cell lymphoma in first remission: an international, multiâ€centre propensityâ€scoreâ€matched study. British Journal of Haematology, 2020, 191, 806-815.	1.2	7
423	Burden and clinical outcomes of hospital-coded infections in patients with cancer: an 11-year longitudinal cohort study at an Australian cancer centre. Supportive Care in Cancer, 2020, 28, 6023-6034.	1.0	7
424	T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease. Bone Marrow Transplantation, 2021, 56, 2857-2859.	1.3	7
425	Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.. Blood, 2006, 108, 2769-2769.	0.6	7
426	Result of FDG PET-CT Imaging After Immunochemotherapy Induction Is a Powerful and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: An Analysis From the PRIMA Study. Blood, 2010, 116, 855-855.	0.6	7
427	Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG). Blood, 2015, 126, 815-815.	0.6	7
428	Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR). Blood, 2016, 128, 2859-2859.	0.6	7
429	Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia. Blood, 2016, 128, 4395-4395.	0.6	7
430	Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2016, 34, 7527-7527.	0.8	7
431	Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study.. Journal of Clinical Oncology, 2017, 35, 7520-7520.	0.8	7
432	Pegylated liposomal doxorubicin in the treatment of cutaneousT-cell lymphoma. Journal of the American Academy of Dermatology, 2001, 44, 149.	0.6	6

#	Article	IF	Citations
433	Interferon-Î±-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia. Annals of Oncology, 2004, 15, 1810-1815.	0.6	6
434	A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy. Haematologica, 2008, 93, 789-790.	1.7	6
435	Chemotherapy Versus Autologous Stem-Cell Transplantation for the Treatment of Transformed Follicular Lymphoma in the Rituximab Era. Journal of Clinical Oncology, 2013, 31, 3166-3167.	0.8	6
436	Response in patients with BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab. Haematologica, 2020, 105, e382-e383.	1.7	6
437	Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15. European Journal of Cancer, 2021, 152, 129-138.	1.3	6
438	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Blood, 2018, 132, LBA-7-LBA-7.	0.6	6
439	The Adverse Effect of High Sokal Risk for First Line Imatinib Treated Patients Is Overcome By a Rapid Rate of BCR-ABL Decline Measured As Early As 1 Month of Treatment. Blood, 2014, 124, 816-816.	0.6	6
440	Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood, 2016, 128, 2033-2033.	0.6	6
441	Treatment of high-risk MDS patients (pts) with -7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): Effects on overall survival (OS). Journal of Clinical Oncology, 2008, 26, 7033-7033.	0.8	6
442	Time-dependent decision analysis: Stable disease in azacitidine (AZA)-treated patients (pts) with higher-risk MDS.. Journal of Clinical Oncology, 2010, 28, 6503-6503.	0.8	6
443	Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study. Blood, 2019, 134, 3999-3999.	0.6	6
444	Lymphomatous Presentation of CD4+/CD8+ HTLV-1-Related Adult T-cell Leukemia/Lymphoma in an Iranian Woman. Leukemia and Lymphoma, 1994, 12, 471-476.	0.6	5
445	Hypercalcemia in acute lymphoblastic leukemia. Leukemia Research, 1994, 18, 231-232.	0.4	5
446	Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. Leukemia, 1998, 12, 1331-1332.	3.3	5
447	High-dose therapy and autologous transplantation for lymphoma: The Peter MacCallum Cancer Institute experience. Internal Medicine Journal, 2001, 31, 279-289.	0.5	5
448	Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide. British Journal of Haematology, 2003, 123, 747-748.	1.2	5
449	Autografting followed by rituximab for chemosensitive mantle cell lymphoma: A pilot study and literature review. Leukemia and Lymphoma, 2005, 46, 851-860.	0.6	5
450	The infectious consequences of rituximab addition to fludarabine-containing regimens. Blood, 2006, 107, 3013-3014.	0.6	5

#	Article	IF	Citations
451	Indolent Lymphomas Other than Follicular and Marginal Zone Lymphomas. Hematology/Oncology Clinics of North America, 2008, 22, 903-940.	0.9	5
452	What is the role of18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?. Leukemia and Lymphoma, 2008, 49, 1653-1656.	0.6	5
453	Under-recognition of platelet dysfunction in myelodysplastic syndromes: are we only seeing the tip of the iceberg?. Leukemia and Lymphoma, 2013, 54, 11-13.	0.6	5
454	<scp>S</scp>tatin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: <scp>A</scp>n exploratory analysis of the PRIMA cohort study. American Journal of Hematology, 2016, 91, 410-415.	2.0	5
455	Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy. Leukemia and Lymphoma, 2016, 57, 1044-1053.	0.6	5
456	Primary Breast Lymphomaâ€”Population-Level Insights into an Infrequent but Increasingly Recognized Subtype of Lymphoma. Journal of the National Cancer Institute, 2017, 109, .	3.0	5
457	Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 1412-1423.	0.6	5
458	Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies. Blood Cancer Journal, 2018, 8, 84.	2.8	5
459	The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment. Cancers, 2019, 11, 928.	1.7	5
460	A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplantâ€eligible patients with previously untreated mantle cell lymphoma. Hematological Oncology, 2019, 37, 253-260.	0.8	5
461	A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents. Hematological Oncology, 2021, 39, 595-604.	0.8	5
462	Evaluation of the Impact of Magnetic Resonance Imaging with Susceptibility-weighted Imaging for Screening and Surveillance of Radiation-induced Cavernomas in Long-term Survivors of Malignancy. Clinical Oncology, 2021, 33, e425-e432.	0.6	5
463	Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab. Blood, 2018, 132, 183-183.	0.6	5
464	Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 3134-3134.	0.6	5
465	Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax. Blood, 2019, 134, 171-171.	0.6	5
466	The Addition of Systemic High-Dose Methotrexate (HD-MTX) to Intrathecal Chemotherapy (IT) for Central Nervous System (CNS) Prophylaxis Substantilly Reduces CNS Recurrence Rates in Patients with at-Risk Aggressive Lymphoma: A Historically Controlled Prospective Study. Blood, 2008, 112, 3596-3596.	0.6	5
467	Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR). Blood, 2008, 112, 3636-3636.	0.6	5
468	Achievement of Red Blood Cell (RBC) Transfusion Independence with Azacitidine (AZA) Leads to Improved Survival In Patients with Higher-Risk Myelodysplasias Regardless of Baseline Transfusion Needs. Blood, 2010, 116, 1856-1856.	0.6	5

#	Article	IF	Citations
469	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. Blood, 2016, 128, 3027-3027.	0.6	5
470	Promises and pitfalls of targeted agents in chronic lymphocytic leukemia. , 2020, 3, 415-444.		5
471	Duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet, The, 1992, 340, 1296-1297.	6.3	4
472	A phase II study of liposomal doxorubicin, vincristine and dexamethasone in multiple myeloma. Leukemia and Lymphoma, 2005, 46, 945-947.	0.6	4
473	Preliminary experience of 18F-fluorodeoxyglucose positron emission tomography in Castleman's disease. Leukemia and Lymphoma, 2006, 47, 2664-2666.	0.6	4
474	Alveolar Soft-Part Sarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 422-423.	0.6	4
475	101 years of McCrae's (not Auer's) rods. British Journal of Haematology, 2006, 133, 690-690.	1.2	4
476	The Late Effects Clinic in action: For survivors of childhood malignancy. Acta OncolÃ³gica, 2007, 46, 1152-1158.	0.8	4
477	Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine. European Journal of Haematology, 2011, 87, 186-188.	1.1	4
478	ConcomitantFIP1L1â€“PDGFRAfusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib. Leukemia and Lymphoma, 2011, 52, 335-338.	0.6	4
479	Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML. Leukemia, 2012, 26, 362-365.	3.3	4
480	No evidence for DNA methylation of theATMpromoter CpG island in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 1420-1422.	0.6	4
481	High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?. Leukemia and Lymphoma, 2013, 54, 2575-2576.	0.6	4
482	Dasatinib therapy can result in significant pulmonary toxicity. American Journal of Hematology, 2015, 90, E224-5.	2.0	4
483	Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology, 2015, 20, 129-136.	0.7	4
484	Editor in Chief: Response to EyreetÂal. â€œALK-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric diseaseâ€. European Journal of Haematology, 2015, 94, 86-87.	1.1	4
485	High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia â€“ lessons for immunopathogenesis and prescribing. Leukemia and Lymphoma, 2019, 60, 3455-3460.	0.6	4
486	A predictive tool for early-stage CLL. Blood, 2020, 135, 1820-1821.	0.6	4

#	Article	IF	Citations
487	Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.. Journal of Clinical Oncology, 2021, 39, 7534-7534.	0.8	4
488	BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood, 2020, 136, 9-10.	0.6	4
489	Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).. Blood, 2005, 106, 920-920.	0.6	4
490	Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2013, 122, 4353-4353.	0.6	4
491	Maintenance Lenalidomide for Adults Aged 18-65 Years with AML in First Complete Remission after Intensive Chemotherapy: A Phase Ib Dose-Escalation Study of the Australasian Leukemia and Lymphoma Group (ALLG). Blood, 2014, 124, 944-944.	0.6	4
492	Rituximab and progressive multifocal leukoencephalopathy: A report of 35 cases. Journal of Clinical Oncology, 2008, 26, 8531-8531.	0.8	4
493	A Phase II, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of the Combination of Tisagenlecleucel and Ibrutinib in Mantle Cell Lymphoma (TARMAC). Blood, 2020, 136, 34-35.	0.6	4
494	New treatment approaches to indolent non-Hodgkin's lymphoma. Seminars in Oncology, 2004, 31, 27-32.	0.8	4
495	Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in Australia. Cancers, 2022, 14, 2710.	1.7	4
496	Paraffin Section Immunotyping of Leukaemias. British Journal of Haematology, 2000, 109, 267-271.	1.2	3
497	Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independent data set. Leukemia, 2008, 22, 2259-2260.	3.3	3
498	Fludarabine, cyclophosphamide, and rituximab chemotherapy followed by rituximab maintenance in follicular lymphoma: high efficacy may come at a cost?. Leukemia and Lymphoma, 2011, 52, 729-731.	0.6	3
499	Rituximab maintenance therapy for follicular lymphoma â€“ Authors' reply. Lancet, The, 2011, 377, 1151-1152.	6.3	3
500	Strategies to optimize collection of hematopoietic stem cells in patients with mantle cell lymphoma receiving hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate-chemotherapy. Leukemia and Lymphoma, 2011, 52, 935-937.	0.6	3
501	Rapid detection of FLT3 exon 20 tyrosine kinase domain mutations in patients with acute myeloid leukemia by high-resolution melting analysis. Leukemia and Lymphoma, 2012, 53, 1225-1229.	0.6	3
502	A case of chronic lymphocytic leukemia associated with systemic light chain amyloidosis. Leukemia and Lymphoma, 2013, 54, 2062-2064.	0.6	3
503	A Risk-Adapted Protocol for Delayed Administration of Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 42-47.	0.2	3
504	Rituximab for the treatment of follicular lymphoma. Future Oncology, 2013, 9, 1283-1298.	1.1	3

#	Article	IF	Citations
505	Evaluating the place of 18-fluoro-2-deoxy-d-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma. Leukemia and Lymphoma, 2013, 54, 2093-2095.	0.6	3
506	De novoB-cell prolymphocytic leukemia with central nervous system involvement. Leukemia and Lymphoma, 2014, 55, 1665-1667.	0.6	3
507	Large B-cell lymphoma: is the future written in the blood?. Lancet Oncology, The, 2015, 16, 481-483.	5.1	3
508	â€œReversibleâ€•myelodysplastic syndrome or ineffectual clonal haematopoiesis? â€“ add(6p) myeloid neoplasm with a spontaneous cytogenetic remission. Leukemia Research, 2018, 73, 1-4.	0.4	3
509	Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy. EJHaem, 2021, 2, 266-271.	0.4	3
510	A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial. Blood, 2018, 132, 2872-2872.	0.6	3
511	Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers. Blood, 2019, 134, 2791-2791.	0.6	3
512	Plerixafor Plus Single-Dose Pegfilgrastim for Hematopoietic Stem and Progenitor Cell Mobilization: An Efficient and Safe Regimen In Good and Poor Mobilizer Patients. Blood, 2010, 116, 2256-2256.	0.6	3
513	Final Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 Trial: All-Trans Retinoic Acid (ATRA), Intravenous Arsenic Trioxide (ATO) and Idarubicin (IDA) As Initial Therapy for Acute Promyelocytic Leukemia (APL). Blood, 2014, 124, 375-375.	0.6	3
514	Multicenter, phase III, open-label, randomized study in relapsed/refractory CLL to evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus rituximab.. Journal of Clinical Oncology, 2014, 32, TPS7120-TPS7120.	0.8	3
515	Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings. Blood, 2020, 136, 37-38.	0.6	3
516	Is BTKi or BCL2i preferable as first novel therapy inÂpatients with CLL? The case for BCL2i. Blood Advances, 2022, 6, 1365-1370.	2.5	3
517	Prolonged diseaseâ€free survival with specific reâ€induction therapy in acute myeloid leukaemia relapsing following bone marrow transplantation. Australian and New Zealand Journal of Medicine, 1997, 27, 712-713.	0.5	2
518	Hodgkin's Disease Complicated by the Nephrotic syndrome in a Man with Kugelberg-Welander Disease. Leukemia and Lymphoma, 2001, 42, 561-566.	0.6	2
519	2007: The year in review forLeukemia and Lymphoma. Leukemia and Lymphoma, 2008, 49, 1-3.	0.6	2
520	Intralesional rituximab for the treatment of localised palatal relapse of follicular lymphoma. Leukemia and Lymphoma, 2009, 50, 303-305.	0.6	2
521	Therapy-related myelodysplasia and fludarabine combination therapy â€“ do the benefits justify the risk?. Leukemia and Lymphoma, 2010, 51, 1957-1959.	0.6	2
522	Osteolytic bone lesions in non-transformed chronic lymphocytic leukemia are not as rare as suggested. Leukemia and Lymphoma, 2012, 53, 1011-1011.	0.6	2

#	Article	IF	Citations
523	Refining the predictors of risk for central nervous system involvement in patients with mantle cell lymphoma. Leukemia and Lymphoma, 2013, 54, 1859-1861.	0.6	2
524	A case of delayed methotrexate clearance following administration of a complementary medication containing chlorophyll. Journal of Oncology Pharmacy Practice, 2014, 20, 225-228.	0.5	2
525	Fast-Track Rapid Warfarin Reversal for Elective Surgery: Extending the Efficacy Profile to High-Risk Patients with Cancer. Anaesthesia and Intensive Care, 2015, 43, 712-718.	0.2	2
526	Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry. Leukemia and Lymphoma, 2018, 59, 992-995.	0.6	2
527	Management of Pregnancy in Women With Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2018, 36, 2657-2658.	0.8	2
528	The evolving definition of bulky disease for lymphoma. Leukemia and Lymphoma, 2020, 61, 1525-1528.	0.6	2
529	Tumor lysis syndrome: still the Achilles heel of venetoclax in treatment of CLL?. Leukemia and Lymphoma, 2020, 61, 2286-2288.	0.6	2
530	Venetoclax plus obinutuzumab therapy for front-line treatment of chronic lymphocytic leukaemia. Lancet Oncology, The, 2020, 21, 1128-1130.	5.1	2
531	First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study. Blood, 2018, 132, 185-185.	0.6	2
532	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC). Blood, 2019, 134, 400-400.	0.6	2
533	The Frequency, Manifestations and Duration of Prolonged Cytopenias after First Line Fludarabine-Combination Chemotherapy for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma. Blood, 2008, 112, 3176-3176.	0.6	2
534	The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 3754-3754.	0.6	2
535	Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR). Blood, 2016, 128, 1638-1638.	0.6	2
536	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 1874-1874.	0.6	2
537	Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax. Blood, 2016, 128, 3223-3223.	0.6	2
538	Splenomegaly, Eosinophilia, and Pruritis: Hodgkin's Disease, or ...?. Blood, 1997, 90, 1719-1720.	0.6	2
539	High, durable minimal residual disease negativity (MRDâ€“) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.. Journal of Clinical Oncology, 2018, 36, 7508-7508.	0.8	2
540	Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results.. Journal of Clinical Oncology, 2020, 38, 8028-8028.	0.8	2

#	Article	IF	Citations
541	A Quality-Adjusted Survival (Q-TWiST) Analysis to Assess Benefit-Risk of Acalabrutinib Versus Idelalisib/Bendamustine Plus Rituximab or Ibrutinib Among Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Patients. Blood, 2021, 138, 3722-3722.	0.6	2
542	High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia. Blood, 2020, 136, 15-16.	0.6	2
543	CLL12: a positive answer to a poorly phrased question. Blood, 2022, 139, 151-152.	0.6	2
544	Central nervous system manifestations of systemic haematological malignancies and key differentials. Clinical Radiology, 2022, , .	0.5	2
545	Progress in management of acute myeloid leukaemia (AML) in Australia since 1980: a single institution retrospective study. Australian and New Zealand Journal of Medicine, 1998, 28, 190-196.	0.5	1
546	Long-term pamidronate in multiple myeloma.. Journal of Clinical Oncology, 1998, 16, 2572-2573.	0.8	1
547	Dosing schedule of oral valacyclovir for prevention of herpes simplex virus. Bone Marrow Transplantation, 2003, 32, 1035-1035.	1.3	1
548	Legionella pneumophila mip gene sequencing to investigate a cluster of pneumonia cases. Pathology, 2003, 35, 65-69.	0.3	1
549	Clonal â€œdevolutionâ€•in a case of essential thrombocythemia with transformation from refractory cytopenia with multilineage dysplasia to acute myeloid leukemia. Leukemia and Lymphoma, 2006, 47, 1160-1162.	0.6	1
550	Follicular lymphoma: maintenance therapy is (often) indicated. Nature Reviews Clinical Oncology, 2009, 6, 624-626.	12.5	1
551	Unresolved issues in the comparison of therapies and determination of responses in WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2010, 51, 1767-1770.	0.6	1
552	Local experience with the novel human antiâ€CD20 antibody, ofatumumab, as salvage treatment for patients with heavily pretreated chronic lymphocytic leukaemia. Internal Medicine Journal, 2012, 42, 846-848.	0.5	1
553	Concerns regarding data supporting recent Pneumocystis jirovecii prophylaxis guidelines. Annals of Hematology, 2013, 92, 1569-1570.	0.8	1
554	Adding weight to a sinking ship: more reasons not to perform routine surveillance imaging in patients with diffuse large B-cell lymphoma in remission. Leukemia and Lymphoma, 2014, 55, 2223-2225.	0.6	1
555	Ongoing challenge of optimal patient selection for CNS prophylaxis in patients with non-Hodgkin lymphoma. International Journal of Hematologic Oncology, 2014, 3, 189-201.	0.7	1
556	An uncomplicated pregnancy in a woman with smoldering WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2015, 56, 2222-2224.	0.6	1
557	Follicular lymphoma: is peripheral blood involvement still an adverse prognostic factor in the rituximab era?. Leukemia and Lymphoma, 2015, 56, 1919-1921.	0.6	1
558	Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia. Contemporary Clinical Trials Communications, 2016, 4, 9-13.	0.5	1

#	Article	IF	Citations
559	Copper deficiency mimicking myelodysplastic syndrome. Leukemia and Lymphoma, 2016, 57, 1223-1226.	0.6	1
560	Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?. Annals of Oncology, 2017, 28, 920-921.	0.6	1
561	Venetoclax for the treatment of mantle cell lymphoma. Annals of Lymphoma, 2019, 3, 4-4.	4.5	1
562	Incorporating Novel Targeted and Immunotherapeutic Agents in the Treatment of B-Cell Lymphomas. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 310-327.	1.8	1
563	The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLL. Leukemia and Lymphoma, 2021, 62, 1-4.	0.6	1
564	Long-Term Follow-up of Patients with Mantle Cell Lymphoma Treated with Venetoclax Monotherapy. Blood, 2018, 132, 2883-2883.	0.6	1
565	Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study. Blood, 2019, 134, 5268-5268.	0.6	1
566	Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial. Blood, 2019, 134, 356-356.	0.6	1
567	Neoantigens Are Typically Associated with Intact HLA Class I Presentation in Early-Stage Follicular Lymphoma. Blood, 2020, 136, 37-38.	0.6	1
568	Incidence, Natural History and Management of Cytomegalovirus (CMV) Dnaemia and Disease in Patients with Haematological Malignancies in the Non-Allogeneic Transplantation Setting.. Blood, 2004, 104, 3837-3837.	0.6	1
569	Utility of Flow Cytometry (FC) in the Assessment of Therapeutic Efficacy in Myelodysplastic Syndromes (MDS) After Therapeutic Intervention.. Blood, 2009, 114, 2767-2767.	0.6	1
570	Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL,. Blood, 2011, 118, 3673-3673.	0.6	1
571	The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Blood, 2015, 126, 3905-3905.	0.6	1
572	Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients. Blood, 2016, 128, 4196-4196.	0.6	1
573	Development of neuropathy in patients (pts) with multiple myeloma (MM) treated with thalidomide (thal)â€"Patterns of occurrence and the role of electrophysiologic monitoring. Journal of Clinical Oncology, 2006, 24, 7618-7618.	0.8	1
574	Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA). Journal of Clinical Oncology, 2008, 26, 7028-7028.	0.8	1
575	Relationship of progression to acute myeloid leukemia (AML) from myelodysplastic syndrome (MDS) and cytogenetic status. Journal of Clinical Oncology, 2008, 26, 7089-7089.	0.8	1
576	A phase 2 open-label study of the efficacy of ABT-199 (GDC-0199) in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) harboring 17p deletion.. Journal of Clinical Oncology, 2014, 32, TPS7121-TPS7121.	0.8	1

#	Article	IF	Citations
577	Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethylating agent (HMA).. Journal of Clinical Oncology, 2017, 35, 7056-7056.	0.8	1
578	Venetoclax (VEN) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2017, 35, e19041-e19041.	0.8	1
579	Ancestim (SCF) and High-Dose Twice-Daily Filgrastim (G-CSF) Is Superior to G-CSF Alone or Cyclophosphamide Plus G-CSF for Mobilization of Peripheral Blood Stem Cells (PBSC) in Patients with Indolent Lymphoproliferative Disorders Previously Treated with Fludarabine; Results of a Historically-Controlled Phase-II Study.. Blood, 2006, 108, 3066-3066.	0.6	1
580	Fludarabine Based Combinations Are Highly Effective as First-Line or Salvage Treatment in Patients with Waldenstrol`m Macroglobulinemia. Blood, 2008, 112, 4947-4947.	0.6	1
581	Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk. Blood, 2010, 116, 4031-4031.	0.6	1
582	Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study. Blood, 2012, 120, 3808-3808.	0.6	1
583	Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged â‰¥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study. Blood, 2016, 128, 2818-2818.	0.6	1
584	Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL.. Journal of Clinical Oncology, 2018, 36, 7526-7526.	0.8	1
585	Impact of Post-Transplant Consolidative Radiotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma and a PET-CT Based Predictive Model for Relapse. Blood, 2019, 134, 4044-4044.	0.6	1
586	Intratumoral Tâ€cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large Bâ€cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (Râ€CHOP) chemoimmunotherapy. Clinical and Translational Immunology, 2021, 10, e1351.	1.7	1
587	Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia. Clinical Advances in Hematology and Oncology, 2019, 17, 440-443.	0.3	1
588	Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas. Cancers, 2022, 14, 1276.	1.7	1
589	Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. Leukemia and Lymphoma, 2022, 63, 676-683.	0.6	1
590	Re: Cure of Helicobacter pylori Infection and Duration of Remission in Low-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Journal of the National Cancer Institute, 1998, 90, 163-164.	3.0	0
591	Could lymphoma be the underlying disease in this patient with pyrexia of unknown origin?. Internal Medicine Journal, 2005, 35, 509-511.	0.5	0
592	Happy anniversary to the 10th International Conference on Malignant Lymphoma in Lugano, 4â€“7 June 2008With a personal tribute to the conference president and founder â€“ Professor Franco Cavalli. Leukemia and Lymphoma, 2008, 49, 1839-1840.	0.6	0
593	What is responsible for the recent improvements in outlook for patients with follicular lymphoma?. Leukemia and Lymphoma, 2010, 51, 960-962.	0.6	0
594	All is not lost - the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab. European Journal of Haematology, 2013, 91, 189-190.	1.1	0

#	Article	IF	Citations
595	Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?. Leukemia and Lymphoma, 2014, 55, 471-473.	0.6	0
596	Stage I-II follicular lymphoma: an endangered species?. Leukemia and Lymphoma, 2015, 56, 2229-2230.	0.6	0
597	Challenging historical perspectives of the 24-h chemotherapy day: Flexible chemotherapy dose-timing guidelines. Asia-Pacific Journal of Clinical Oncology, 2016, 12, e57-e64.	0.7	0
598	BCL2 Inhibitors: Insights into Resistance. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 23-43.	0.1	0
599	Reply to M. Sorigue et al. Journal of Clinical Oncology, 2019, 37, 257-258.	0.8	0
600	Safety Is the Heart of the Matter. International Journal of Radiation Oncology Biology Physics, 2020, 106, 462-463.	0.4	0
601	Durable Complete Remission and Long-Term Survival in FDG-PET Staged Patients with Stage III Follicular Lymphoma, Treated with Wide-Field Radiation Therapy. Cancers, 2020, 12, 991.	1.7	0
602	Reply to Y. Myoken et al. Journal of Clinical Oncology, 2021, 39, 173-174.	0.8	0
603	A Comparison of Acute and Delayed Infection Rates among Patients with Indolent Lymphoid Malignancies Receiving Fludarabine(F) and Cyclophosphamide(C) with or without Rituximab(R).. Blood, 2004, 104, 3313-3313.	0.6	0
604	Optimal Timing of Peripheral Blood Stem Cell Mobilisation in Patients with Hematological Malignancies Treated with the Hyper-CVAD Chemotherapy Regimen.. Blood, 2004, 104, 5213-5213.	0.6	0
605	A Mid-Treatment FDG-Positron Emission Tomography (PET) Scan Is Highly Predictive of Subsequent Treatment Failure in Patients with Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2005, 106, 1931-1931.	0.6	0
606	Augmented Preparative Regimens Using Total Body Irradiation or BCNU Prior to Autologous Stem Cell Transplant (AuSCT) Are Well-Tolerated and Yield Substantial Rates of Progression-Free Survival in Patients with Poor Risk Hodgkin Lymphoma (HL) or Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2005, 106, 5499-5499.	0.6	0
607	Prolonged Hematologic Toxicity from the Hyper-CVAD Regimen; Manifestations, Frequency, and Natural History in a Cohort of 125 Consecutive Patients.. Blood, 2006, 108, 2441-2441.	0.6	0
608	Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) Monitoring of Minimal Residual Disease (MRD) in Core Binding Factor Acute Myeloid Leukaemia (CBF AML).. Blood, 2006, 108, 2296-2296.	0.6	0
609	A Prospective Study of the Prognostic Impact of 18[F]-FDG-PET and Molecular Response in Patients with Relapsed Indolent Non-Hodgkin Lymphoma (NHL) Following Iodine-131-Rituximab Radio-Immunotherapy (RIT).. Blood, 2007, 110, 3421-3421.	0.6	0
610	Repeat Treatment with Iodine-131-Rituximab Is Safe and Effective in Patients with Relapsed Indolent B-Cell Non-Hodgkin Lymphoma (NHL) Who Had Previously Responded to This Therapy.. Blood, 2007, 110, 3413-3413.	0.6	0
611	Immunophenotyping by flow-cyotmetry in MDS and its potential role in remission assessment post treatment. Journal of Clinical Oncology, 2008, 26, 18008-18008.	0.8	0
612	Gene methylation and cytogenetic abnormalities in patients (pts) with higher-risk myelodysplastic syndromes.. Journal of Clinical Oncology, 2010, 28, 6606-6606.	0.8	0

#	Article	IF	Citations
613	HLA-Class I Alleles Impact Susceptibility To EBV+ Classical Hodgkin Lymphoma By Altering EBV Latent Antigen-Specific CD8+ T-Cell Immune Hierarchies. Blood, 2013, 122, 630-630.	0.6	0
614	Lack Of Benefit From Surveillance PET-CT In Transformed Indolent Lymphoma (TrIL) In Complete Metabolic Remission (CMR) Following Therapy. Blood, 2013, 122, 1796-1796.	0.6	0
615	Net antitumoral immunity and the predictive power of conventional prognosticators in diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2014, 32, 8542-8542.	0.8	0
616	Prevalence and Prognostic Value of BCL2 and MYC Protein Expression within ABC and GCB Subtypes in Patients with Previously Untreated, Diffuse Large B-Cell Lymphoma: Analysis from the Phase III MAIN Study. Blood, 2015, 126, 3971-3971.	0.6	0
617	A randomized, open-label, phase II study of CC-486 (oral azacitidine), alone or in combination with durvalumab (MEDI4736), in patients (pts) with myelodysplastic syndromes (MDS) unresponsive to prior parenteral azacitidine or decitabine.. Journal of Clinical Oncology, 2016, 34, TPS7078-TPS7078.	0.8	0
618	Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival. Blood, 2016, 128, 338-338.	0.6	0
619	Serial Minimal Residual Disease Evaluation in Patients with Chronic Lymphocytic Leukemia Under Long-Term Venetoclax Treatment. Blood, 2018, 132, 1876-1876.	0.6	0
620	Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy. Blood, 2018, 132, 4394-4394.	0.6	0
621	Therapeutic Modulators of Apoptosis and Epigenetics in Aggressive Lymphoma. Springer Reference Medizin, 2019, , 325-341.	0.0	0
622	Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy. Blood, 2019, 134, 4290-4290.	0.6	0
623	Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL). Blood, 2021, 138, 3721-3721.	0.6	0
624	Evaluating the PET Parameters SUVmax and TMTV in the Setting of Autologous Stem Cell Transplantation for DLBCL. Blood, 2020, 136, 38-38.	0.6	0
625	Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies. Blood, 2020, 136, 36-37.	0.6	0
626	Enhancing our chances of picking a winner in higherâ€risk myelodysplastic syndromes. British Journal of Haematology, 2022, , .	1.2	0